Skip to main
  1. Stocks
  2. Microbot Medical
  3. Forecast
MBOT

Microbot Medical (MBOT) Stock Forecast & Price Target

Microbot Medical (MBOT) Analyst Ratings

Based on 5 analyst ratings
Strong Buy
Strong Buy 80%
Buy 20%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Microbot Medical is attractive because LIBERTY addresses major adoption barriers in endovascular robotics by being fully disposable, compact, catheter-agnostic, and priced at $3,500-$4,000 per procedure, unlike capital-heavy systems that require large footprints and service infrastructure. Its clinical and commercial case is strengthened by 100% utilization and reorder rates, a 92% reduction in physician radiation exposure, 100% successful navigation in the pivotal study, and growing U.S. traction with 12 customer accounts and 10 sales territories as of 3Q26. With more than $60 million in cash, no debt, and a recurring-revenue model aimed at a ~2.5 million-procedure peripheral market with <1% robotic penetration, the company appears well funded to scale through the early commercialization phase.

Bears say

Microbot Medical is still in the earliest stages of monetizing LIBERTY, so its revenue base is narrow and highly dependent on a single platform that entered market release in April 2026 while adoption remains unproven. The latest results show deteriorating fundamentals, with gross profit loss widening to $1.0 mln, operating loss rising to $6.5 mln, and net loss at $5.8 mln, while operating expenses climbed 42% y/y to $5.5 mln on heavier commercialization and R&D spending. Its outlook is further pressured by lack of dedicated CMS reimbursement, slow hospital adoption of a single-use robotic system, reliance on third parties and suppliers, and ongoing royalty obligations of 1.5-3.0% of net sales to TRDF.

Microbot Medical (MBOT) has been analyzed by 5 analysts, with a consensus rating of Strong Buy. 80% of analysts recommend a Strong Buy, 20% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Microbot Medical and is not a guaranteed prediction by Public.com or investment advice.

Microbot Medical (MBOT) Analyst Forecast & Price Prediction

Get the latest Microbot Medical (MBOT) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Microbot Medical (MBOT)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Microbot Medical (MBOT) Forecast

Analysts have given Microbot Medical (MBOT) a Strong Buy based on their latest research and market trends.

According to 5 analysts, Microbot Medical (MBOT) has a Strong Buy consensus rating as of Nov 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $5.30, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $5.30, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Microbot Medical (MBOT)


Microbot Medical (MBOT) Analyst Forecast & Price Prediction

Get the latest Microbot Medical (MBOT) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Microbot Medical (MBOT)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover MBOT stock data and trends